Animal models of myositis

Rheumatic Disease Clinics of North America

Volumn 28, Issue 4, 2002, Pages 917-933

  Nagaraju, Kanneboyina ^a   Plotz, Paul H ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; DERMATOMYOSITIS; IDIOPATHIC DISEASE; INCLUSION BODY MYOSITIS; INFLAMMATORY DISEASE; MUSCLE DISEASE; MYOSITIS; NONHUMAN; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; DOG DISEASES; DOGS; FEMALE; HUMANS; MALE; MICE; MICE, INBRED STRAINS; MICE, MUTANT STRAINS; MICE, TRANSGENIC; MYOSITIS;

EID: 0036867987     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(02)00026-1     Document Type: Review

References (78)

1. Nagaraju K. Immunological capabilities of skeletal muscle cells. Acta Physiol Scand 2001;171:215-23.
2. Nagaraju K. Update on immunopathogenesis in inflammatory myopathies. Curr Opin Rheumatol 2001;13:461-8.
3. Targoff IN. Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol 2000;12:475-81.
4. Kornegay JN, Gorgacz EJ, Dawe DL, et al. Polymyositis in dogs. J Am Vet Med Assoc 1980;176:431-8.
5. Haupt KH, Prieur DJ, Hargis AM, et al. Familial canine dermatomyositis: clinicopathologic, immunologic, and serologic studies. Am J Vet Res 1985;46:1870-5.
6. Hargis AM, Haupt KH, Prieur DJ, et al. Animal model of human disease. Dermatomyositis. Familial canine dermatomyositis. Am J Pathol 1985;120:323-5.
7. Hargis AM, Prieur DJ, Haupt KH, et al. Prospective study of familial canine dermatomyositis. Correlation of the severity of dermatomyositis and circulating immune complex levels. Am J Pathol 1986;123:465-79.
8. Gross TL, Kunkle GA. The cutaneous histology of dermatomyositis in collie dogs. Vet Pathol 1987;24:11-5.
9. Ferguson EA, Cerundolo R, Lloyd DH, et al. Dennatomyositis in five Shetland sheepdogs in the United Kingdom. Vet Rec 2000;146:214-7.
10. Rosenberg NL. Neuromuscular histopathology in (New Zealand black x New Zealand white)F1 and MRL-1pr/1pr autoimmune mice: Models for skeletal muscle involvement in connective tissue disease. Arthritis Rheum 1988;31:806-11.
11. Rosenberg NL, Ringel SP, Kotzin BL. Experimental autoimmune myositis in SJL/J mice. Clin Exp Immunol 1987;68:117-29.
12. Rosenberg NL. Experimental models of inflammatory myopathies. Baillieres Clin Neurol 1993;2:693-715.
13. Weller AH, Magliato SA, Bell KP, et al. Spontaneous myopathy in the SJL/J mouse: Pathology and strength loss. Muscle Nerve 1997;20:72-82.
14. Bittner RE, Anderson LV, Burkhardt E, et al. Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. Nat Genet 1999;23:141-2.
15. Vafiadaki E, Reis A, Keers S, et al. Cloning of the mouse dysferlin gene and genomic characterization of the SJL-Dysf mutation. Neuroreport 2001;12:625-9.
16. Gallardo E, Rojas-Garcia R, De Luna N, et al. Inflammation in dysferlin myopathy: Immunohistochemical characterization of 13 patients. Neurology 2001;57:2136-8.
17. Matsushima GK, Stohlman SA. Distinct subsets of accessory cells activate Thy-1 + triple negative (CD3-, CD4-, CD8-) cells and Th-1 delayed-type hypersensitivity effector T cells. J Immunol 1991;146:3322-31.
18. Manghani D, Partridge TA, Sloper JC. The role of myofibrillar fraction of skeletal muscle in the production of experimental polymyositis. J Neurol Sci 1974;23:489-503.
19. Currie S. Experimental myositis: The in-vivo and in-vitro activity of lymph-node cells. J Pathol 1971;105:169-85.
20. Matsubara S, Takamori M. Experimental allergic myositis: Strain 13 guinea pig immunised with rabbit myosin B fraction. Acta Neuropathol (Berl) 1987;74:158-62.
21. Matsubara S, Shima T, Takamori M. Experimental allergic myositis in SJL/J mice immunized with rabbit myosin B fraction: Immunohistochemical analysis and transfer. Acta Neuropathol (Berl) 1993;85:138-44.
22. Matsubara S, Okumura S. Experimental autoimmune myositis in SJL/J mice produced by immunization with syngeneic myosin B fraction. Transfer by both immunoglobulin G and T cells. J Neurol Sci 1996;144:171-5.
23. Kohyama K, Matsumoto Y. C-protein in the skeletal muscle induces severe autoimmune polymyositis in Lewis rats. J Neuroimmunol 1999;98:130-5.
24. Kojima T, Tanuma N, Aikawa Y, et al. Myosin-induced autoimmune polymyositis in the rat. J Neurol Sci 1997;151:141-8.
25. Kawachi I, Tanaka K, Tanaka M, et al. Dendritic cells presenting pyruvate kinase M1/M2 isozyme peptide can induce experimental allergic myositis in BALB/c mice. J Neuroimmunol 2001;117:108-15.
26. Davis LE, Kornfeld M. Experimental influenza B viral myositis. J Neurol Sci 2001;187:61-7.
27. Ray CG, Minnich LL, Johnson PC. Selective polymyositis inducted by coxsackievirus B1 in mice. J Infect Dis 1979;140:239-43.
28. Strongwater SL, Dorovini-Zis K, Ball RD, et al. A murine model of polymyositis induced by coxsackievirus B1 (Tucson strain). Arthritis Rheum 1984;27:433-42.
29. Miller FW, Love LA, Biswas T, et al. Viral and host genetic factors influence encephalomyocarditis virus-induced polymyositis in adult mice. Arthritis Rheum 1987;30:549-56.
30. Podell M, Chen E, Shelton GD. Feline immunodeficiency virus associated myopathy in the adult cat. Muscle Nerve 1998;21:1680-5.
31. Dalakas MC, London WT, Gravell M, et al. Polymyositis in an immunodeficiency disease in monkeys induced by a type D retrovirus. Neurology 1986;36:569-72.
32. McVicker JH, Lava NS, Mittag TW, et al. D-penicillamine-induced neuromuscular disease in guinea pigs. Exp Neurol 1982;76:46-57.
33. Blechynden LM, Lawson MA, Tabarias H, et al. Myositis induced by naked DNA immunization with the gene for histidyl-tRNA synthetase. Hum Gene Ther 1997;8:1469-80.
34. Nagaraju K, Raben N, Loeffler L, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci USA 2000;97:9209-14.
35. Shelton GD, Calcutt NA, Garrett RS, et al. Necrotizing myopathy induced by overexpression of interferon-gamma in transgenic mice. Muscle Nerve 1999;22:156-65.
36. Jin LW, Hearn MG, Ogburn CE, et al. Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis. Am J Pathol 1998;153:1679-86.
37. Fukuchi K, Pham D, Hart M, et al. Amyloid-beta deposition in skeletal muscle of transgenic mice: Possible model of inclusion body myopathy. Am J Pathol 1998;153:1687-93.
38. Chiesa R, Pestronk A, Schmidt RE, et al. Primary myopathy and accumulation of PrPSc-like molecules in peripheral tissues of transgenic mice expressing a prion protein insertional mutation. Neurobiol Dis 2001;8:279-88.
39. Ishihara T, Hong M, Zhang B, et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 1999;24:751-62.
40. Capsoni S, Ugolini G, Comparini A, et al. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc Natl Acad Sci USA 2000;97:6826-31.
41. Hoefler G, Noehammer C, Levak-Frank S, et al. Muscle-specific overexpression of human lipoprotein lipase in mice causes increased intracellular free fatty acids and induction of peroxisomal enzymes. Biochimie 1997;79:163-8.
42. Lang RA, Metcalf D, Cuthbertson RA, et al. Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage. Cell 1987;51:675-86.
43. Nerenberg MI, Wiley CA. Degeneration of oxidative muscle fibers in HTLV-1 tax transgenic mice. Am J Pathol 1989;135:1025-33.
44. Bothe K, Aguzzi A, Lassmann H, et al. Progressive encephalopathy and myopathy in transgenic mice expressing human foamy virus genes. Science 1991;253:555-7.
45. Kvist AP, Latvanlehto A, Sund M, et al. Lack of cytosolic and transmembrane domains of type XIII collagen results in progressive myopathy. Am J Pathol 2001;159:1581-92.
46. Metcalf D, Di Rago L, Mifsud S, et al. The development of fatal myocarditis and polymyositis in mice heterozygous for IFN-gamma and lacking the SOCS-1 gene. Proc Natl Acad Sci USA 2000;97:9174-9.
47. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995;270:985-8.
48. Kulkarni AB, Huh CG, Becker D, et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993;90:770-4.
49. Boehme DH. Possibilities and limitations of production ofautoimmune diseases in inbred mouse strains. Pathol Eur 1966;1:119-34.
50. Dawkins RL. Experimental myositis associated with hypersensitivity to muscle. J Pathol Bacteriol 1965;90:619-25.
51. Webb JN. In vitro transformation of lymphocytes in experimental immune myositis. J Reticuloendothel Soc 1970;7:445-52.
52. Webb JN. Phagocytosis factor in the serum of guinea pigs in experimental immune myositis. J Reticuloendothel Soc 1970;7:317-27.
53. Morgan G, Peter JB, Newbould BB. Experimental allergic myositis in rats. Arthritis Rheum 1971;14:599-609.
54. Kalden JR, Williamson WG, Irvine WJ. Experimental myasthenia gravis, myositis and myocarditis in guinea-pigs immunized with subcellular fractions of calf thymus or calf skeletal muscle in Freund's complete adjuvant. Clin Exp Immunol 1973;13:79-88.
55. Esiri MM, Maclennan IC. Experimental myositis in rats. II. The sensitivity of spleen cells to syngeneic muscle antigen. Clin Exp Immunol 1975;19:513-20.
56. Esiri MM, Maclennan IC. Experimental myositis in rats. I. Histological and creatine phosphokinase changes, and passive transfer to normal syngeneic rats. Clin Exp Immunol 1974;17:139-50.
57. Manghani D, Partridge TA, Sloper JC. The role of myofibrillar fraction of skeletal muscle in the production of experimental polymyositis. J Neurol Sci 1974;23:489-503.
58. Smith PD, Partridge TA. Macrophage migration inhibition studies of lymphocytes taken from guinea-pigs suffering from experimental polymyositis. Clin Exp Immunol 1976;25:133-8.
59. Rosenberg NL, Kotzin BL. Aberrant expression of class II MHC antigens by skeletal muscle endothelial cells in experimental autoimmune myositis. J Immunol 1989;142:4289-94.
60. Schneider C, Matsumoto Y, Kohyama K, et al. Experimental autoimmune myositis in the lewis rat: Lack of spontaneous T-cell apoptosis and therapeutic response to glucocorticosteroid application. J Neuroimmunol 2000;107:83-7.
61. Matsubara S, Kitaguchi T, Kawata A, et al. Experimental allergic myositis in SJL/J mouse. Reappraisal of immune reaction based on changes after single immunization. J Neuroimmunol 2001;119:223-30.
62. Wada J, Shintani N, Kikutani K, et al. Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition. Clin Exp Immunol 2001;124:282-9.
63. Nemoto H, Nemoto K, Sugimoto H, et al. FK506 suppressed the inflammatory change of EAM in SJL/J mice. J Neurol Sci 2001;193:7-11.
64. Ludewig B, Junt T, Hengartner H, et al. Dendritic cells in autoimmune diseases. Curr Opin Immunol 2001;13:657-62.
65. Ludewig B, Odermatt B, Ochsenbein AF, et al. Role of dendritic cells in the induction and maintenance of autoimmune diseases. Immunol Rev 1999;169:45-54.
66. Dittel BN, Visintin I, Merchant RM, et al. Presentation of the self antigen myelin basic protein by dendritic cells leads to experimental autoimmune encephalomyelitis. J Immunol 1999;163:32-9.
67. Wakasugi K, Schimmel P. Two distinct cytokines released from a human aminoacyl-tRNA synthetase. Science 1999;284:147-51.
68. Ytterberg SR. Coxsackievirus B 1 induced murine polymyositis: acute infection with active virus is required for myositis. J Rheumatol 1987;14:12-8.
69. Ytterberg SR, Mahowald ML, Messner RP. Coxsackievirus B 1-induced polymyositis. Lack of disease expression in nu/nu mice. J Clin Invest 1987;80:499-506.
70. Tam PE, Schmidt AM, Ytterberg SR, et al. Viral persistence during the developmental phase of Coxsackievirus B1-induced murine polymyositis. J Virol 1991;65:6654-60.
71. Tam PE, Schmidt AM, Ytterberg SR, et al. Duration of virus persistence and its relationship to inflammation in the chronic phase of coxsackievirus B1-induced murine polymyositis. J Lab Clin Med 1994;123:346-56.
72. Cronin ME, Love LA, Miller FW, et al. The natural history of encephalomyocarditis virus-induced myositis and myocarditis in mice. Viral persistence demonstrated by in situ hybridization. J Exp Med 1988;168:1639-48.
73. Hiruma M. Ide S, Hohdatsu T, et al. Polymyositis in mice experimentally inoculated with Getah virus. Nippon Juigaku Zasshi 1990;52:767-72.
74. Seay AR, Griffin DE, Johnson RT. Experimental viral polymyositis: Age dependency and immune responses to Ross River virus infection in mice. Neurology 1981;31:656-60.
75. Ghersa P, Gobert RP, Sattonnet-Roche P, et al. Highly controlled gene expression using combinations of a tissue-specific promoter, recombinant adenovirus and a tetracycline-regulatable transcription factor. Gene Ther 1998;5:1213-20.
76. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995;38:705-13.
77. Eisenberg I, Avidan N, Potikha T, et al. The UDP-N-acetylglucsamine 2-epimerase/N-acetyl-mannosamine kinase gene is mutated i recessive hereditary inclusion body myopathy. Nat Genet 2001;29:83-7.
78. Kulkami AB, Karlsson S. Inflammation and TGF β 1: Lessons from the TGF β 1 null mouse. Res Immunol 1997;148:453-6.